NT-PROBNP AND THE CUT-OFF VALUE IN CARDIOVASCULAR DISEASES

2011 ◽  
pp. 5-12
Author(s):  
Anh Tien Hoang ◽  
Van Minh Huynh ◽  
Khanh Hoang ◽  
Huu Dang Tran ◽  
Viet An Tran
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Pilot Study ◽  
Cardiovascular Diseases ◽  
Clinical Application ◽  
European Society ◽  
The Other ◽  
Cardiac Marker ◽  
Cardiac Biomarker ◽  
European Society Of Cardiology

NT-ProBNP is a high value cardiac biomarker and widely applies in many cardiovascular diseases. The evaluation of concentration of NT-ProBNP needs the concern about age, gender, obesity and especially we need each cut-off point for each cause of cardiovascular disease in evaluation and clinical application. Because NT-ProBNP is a new cardiac marker and has been researched in 5 recent years, the cut-off of NT-ProBNP is still being studied for the clinical application in cardiovascular diseases. Only the cut-off of NT-ProBNP in diagnosis heart failure was guided by European Society of Cardiology. The meaning of introduce cut-off value of value plays an role as pilot study for the other relate study and brings the NT-ProBNP closely approach to clinical application.

The European Society of Cardiology and the European Association for the Study of Diabetes: guidelines for diabetes and cardiovascular diseases

2020 ◽  
Vol 15 (3) ◽  
pp. 1-4
Author(s):  
Belinda Linden
Keyword(s):  
Cardiovascular Disease ◽  
Cardiovascular Diseases ◽  
European Society ◽  
European Association ◽  
European Society Of Cardiology ◽  
Cardiovascular Nursing

Belinda Linden presents a quarterly overview of recently published guidance of relevance to cardiovascular nursing. The significant link between diabetes and cardiovascular disease is reviewed in this update

scholarly journals The Role of Genetics in Cardiomyopaties: A Review

2021 ◽  
Author(s):  
Luis Vernengo ◽  
Haluk Topaloglu
Keyword(s):  
Heart Failure ◽  
Sudden Death ◽  
European Society ◽  
Cardiac Dysfunction ◽  
American Heart Association ◽  
Heart Association ◽  
The Other ◽  
Systemic Disorder ◽  
European Society Of Cardiology

Cardiomyopathies are defined as disorders of the myocardium which are always associated with cardiac dysfunction and are aggravated by arrhythmias, heart failure and sudden death. There are different ways of classifying them. The American Heart Association has classified them in either primary or secondary cardiomyopathies depending on whether the heart is the only organ involved or whether they are due to a systemic disorder. On the other hand, the European Society of Cardiology has classified them according to the different morphological and functional phenotypes associated with their pathophysiology. In 2013 the MOGE(S) classification started to be published and clinicians have started to adopt it. The purpose of this review is to update it.

scholarly journals DYSLIPIDEMIA: OVERVIEW OF THE ESC/EAS 2019 RECOMMENDATIONS FOR DIAGNOSTICS AND TREATMENT. PART 2 – TARGET THERAPY

2021 ◽  
Vol 19 (2) ◽  
pp. 236-241
Author(s):  
V. M. Pyrochkin ◽  
◽  
Y. I. Karpovich ◽  
E. V. Mironchik ◽  
A. V. Kovtun ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Clinical Application ◽  
European Society ◽  
Target Therapy ◽  
European Congress ◽  
European Atherosclerosis Society ◽  
Individual Assessment ◽  
High Incidence ◽  
European Society Of Cardiology

The high incidence of cardiovascular disease leads to a routine individual assessment of the patient's cardiovascular risk, and to the correction of the therapy. In 2019, at the European Congress of Cardiology, updated recommendations of the ESC/EAS (European Society of Cardiology / European Atherosclerosis Society) on the diagnosis and treatment of dyslipidemia were presented, new approaches to cardiovascular risk assessing and correction of dyslipidemia were formulated. The article discusses the main aspects of clinical application of the new recommendations for the treatment of this pathology.

Prevention of atrial fibrillation – non-modifiable and modifiable risk factors for AF

2020 ◽  
Vol 2 (55) ◽  
pp. 14-19
Author(s):  
Agnieszka Wojdyła-Hordyńska ◽  
Grzegorz Hordyński
Keyword(s):  
Risk Factors ◽  
Heart Failure ◽  
Atrial Fibrillation ◽  
Cardiovascular Disease ◽  
Cardiovascular Diseases ◽  
Sudden Cardiac Death ◽  
Cardiac Death ◽  
Combined Treatment ◽  
Lifestyle Changes ◽  
Modifiable Risk Factors

Atrial fibrillation is one of the most common arrhythmias, with a significant increase in incidence in recent years. AF is a major cause of stroke, heart failure, sudden cardiac death, and cardiovascular disease. Timely intervention and modification of risk factors increase chance to stop the disease. Aggressive, multilevel prevention tactics are a component of combined treatment, including – in addition to lifestyle changes, anticoagulant therapy, pharmacotherapy and invasive anti-arrhythmic treatment – prevention of cardiovascular diseases, hypertension, ischemia, valvular disease and heart failure.

Sign in / Sign up

Export Citation Format

Share Document